Osimertinib, the original name of commodity: Tagrisso, r&d code: AZD9291.This is astrazeneca TKI targeted drug research and development and production of the third generation, is a kind of oral and irreversible, the third generation of EGFR inhibitors (EGFR - TKI), clinical effect is remarkable.It is against the T790M mutation of the third generation of TKI kind of targeted drugs, mainly used for the treatment of advanced non-small cell lung cancer (NSCLC).
T790M mutation is the most common are long-term use Yi Rui sand, kay beauty or patients with tarceva.Taking Yi Rui sand, kay beauty or tarceva 1-2 years or so, about 55-60% of patients will produce T790M mutation, the original targeted drugs will be invalid, or can occasionally result in drug resistance problems, tumor lesion and uncontrolled, Mr Bush for is dedicated to solve this problem, provide a new treatment for the patient.
Indications: for the patients with tumor
Specification: 80 mg * 30 grains
Retail price: $200
Note: Osimertinib original name of commodity: Tagrisso (gray tower)